QURE Stock Risk & Deep Value Analysis
Uniqure NV
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About QURE Stock
We analyzed Uniqure NV using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran QURE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
QURE Risk Analysis & Red Flags
What Could Go Wrong
The FDA's requirement for additional studies for AMT-130 could significantly delay or even derail the program, leading to further substantial capital burn without a clear path to profitability. Combined with ongoing class-action lawsuits, this could lead to prolonged stock underperformance and necessitate highly dilutive capital raises.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
FDA public criticism of AMT-130 study design and BLA delay
- ⚠
Multiple securities class action lawsuits alleging misrepresentation
- ⚠
FY2025 revenue decline of 40.6% YoY with -1236.2% net margin
- ⚠
Form 144 filed by an insider indicating potential sale intent
Upcoming Risk Events
- 📅
Unfavorable outcomes in securities class action lawsuits
- 📅
Further negative feedback or delays from the FDA for AMT-130
- 📅
Need for additional capital raise leading to significant shareholder dilution
When to Reconsider
- 🚪
Exit if the FDA issues a Complete Response Letter (CRL) for AMT-130 without a clear path forward
- 🚪
Sell if cash runway shortens to less than 12 months without a clear funding plan
- 🚪
Exit if quarterly revenue (excluding one-time milestones) continues to decline or stagnate
Unlock QURE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Uniqure NV (QURE) Do?
Market Cap
$1.14B
Sector
Healthcare
Industry
Biotechnology
Employees
209
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Visit Uniqure NV WebsiteInvestment Thesis
uniQure represents a high-risk, high-reward bet on the long-term success of its gene therapy pipeline, particularly AMT-130 for Huntington's disease, despite significant recent regulatory setbacks and ongoing legal challenges. The company's proprietary AAV5 platform and existing revenue from Hemgenix provide a speculative foundation for potential future growth if it successfully navigates its current hurdles and restores confidence in its lead program.
Is QURE Stock Undervalued?
Unlock the full AI analysis for QURE
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
QURE Price Targets & Strategy
12-Month Target
$35.00
Bull Case
$45.00
Bear Case
$10.00
Valuation Basis
Based on a risk-adjusted average of analyst price targets, reflecting anticipated, albeit delayed, progress for AMT-130 and sustained Hemgenix royalties.
Entry Strategy
Consider dollar-cost averaging in the $16-$19 range, near recent support levels, but only for investors with high risk tolerance given the current uncertainties.
Exit Strategy
Take partial profits if the stock reaches $35-$40 following positive regulatory or litigation news; set a stop-loss order if the price consistently breaks below $15, indicating further deterioration.
Portfolio Allocation
2-4% for aggressive risk tolerance only, given the significant clinical and legal risks.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is QURE Financially Healthy?
Valuation
P/E Ratio
-4.97
Price/Book
6.92
Price/Sales
87.56
Profitability
Gross Margin
89.53%
Operating Margin
-1151.38%
Net Margin
-1236.00%
Return on Equity
-104.86%
Revenue Growth
-40.64%
EPS
$-3.48
Balance Sheet
Current Ratio
10.43
Quick Ratio
10.10
Debt/Equity
2.63
Cash Flow
EBITDA
-$154.37M
Other
Beta (Volatility)
0.71
Does QURE Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable (inherent platform value) but under pressure from execution and regulatory challenges for key assets.
Moat Sources
1 Identified
The AAV5 platform and existing gene therapy intellectual property provide a degree of durability. However, the rapidly evolving gene therapy landscape and the high bar for regulatory approval mean that a single product setback can significantly erode the perceived value and future revenue potential derived from this moat.
Moat Erosion Risks
- •Clinical trial failures or significant regulatory delays for pipeline assets
- •Emergence of superior or more cost-effective competing therapies
- •Patent expirations or challenges to intellectual property
QURE Competitive Moat Analysis
Sign up to see competitive advantages
QURE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (due to the regulatory setbacks and lawsuits, despite long-term gene therapy potential)
Institutional Sentiment
Mixed (Moderate Buy consensus from analysts, but Cantor Fitzgerald significantly cut target, while some like Wells Fargo upgraded. Aberdeen Group increased stake, but a Form 144 indicates potential insider selling.)
Insider Activity (Form 4)
Form 144 filed by Christian Klem t (title unspecified) on Feb 25, 2026, indicating potential sale intent. Aberdeen Group plc bought 738,897 shares on or before April 4, 2026, increasing their stake to ~5.91% ownership.
Options Flow
Normal options activity (no specific unusual options activity reported in research).
Earnings Intelligence
Next Earnings
No consensus estimates or expected date available in search results. Historically, Q1 earnings would be in early May.
Surprise Probability
Low (Given the current uncertainty around AMT-130 and the negative revenue trend, surprises are less likely to be positive and significant.)
Historical Earnings Pattern
No specific historical pattern available, but highly sensitive to clinical trial and regulatory news, evidenced by the 49% stock drop on Nov 3, 2025.
Key Metrics to Watch
Competitive Position
Top Competitor
Not provided in the research data.
Market Share Trend
Stable in current commercialized products (Hemgenix via CSL Behring) but losing ground in perceived future market share for AMT-130 due to regulatory delays.
Valuation vs Peers
Trading at a significant premium on current Price/Sales (68x on FY2025 revenue) compared to many profitable biotech peers, reflecting high expectations for future pipeline success, which is now significantly challenged.
Competitive Advantages
- •Proprietary AAV5 gene therapy platform
- •Approved gene therapy product (Hemgenix) validating technology
- •Focus on rare, severe diseases with high unmet need
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive QURE Stock Higher?
Near-Term (0-6 months)
- •FY2026 Q1 Earnings Report (Expected early-May 2026)
- •Updates on ongoing securities class action lawsuits (Ongoing)
- •Progress on FDA feedback regarding AMT-130 study design
Medium-Term (6-18 months)
- •Resolution or significant progress in legal challenges (6-18 months)
- •Potential initiation of additional studies for AMT-130 (6-18 months)
- •Updates on Hemgenix royalty performance and milestones
Long-Term (18+ months)
- •Potential BLA resubmission and approval for AMT-130 (18+ months)
- •Expansion of AAV5 platform into new therapeutic areas
- •Commercialization of AMT-130 for Huntington's disease
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for QURE?
- ✓
Positive updates from the FDA regarding AMT-130's clinical path
- ✓
Resolution of ongoing legal disputes without significant financial impact
- ✓
Signs of an improving cash burn rate or successful, non-dilutive financing
Bull Case Analysis
See what could go right with Premium
Competing with QURE
See how Uniqure NV compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Uniqure NV QURE | $1.1B | 5.0 | -5.0 | $16.1M | -1236.0% | -40.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Uniqure NV Makes Money
uniQure NV is a biopharmaceutical company focused on developing and commercializing gene therapies for patients suffering from serious genetic diseases. They primarily generate revenue through milestones and royalties from their approved gene therapy, Hemgenix, which is commercialized by CSL Behring. Additionally, they invest heavily in research and development to advance their pipeline of gene therapies, with AMT-130 for Huntington's disease being their lead investigational product, aiming for future direct product sales upon successful regulatory approval.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Uniqure NV (QURE)?
As of April 28, 2026, Uniqure NV has a DVR Score of 5.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Uniqure NV?
Uniqure NV's market capitalization is approximately $1.1B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Uniqure NV use?
QURE is the ticker symbol for Uniqure NV. The company trades on the NMS.
What is the risk level for QURE stock?
Our analysis rates Uniqure NV's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of QURE?
Uniqure NV currently has a price-to-earnings (P/E) ratio of -5.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Uniqure NV's revenue growing?
Uniqure NV has reported revenue growth of -40.6%. Revenue has been declining, which warrants closer examination.
Is QURE stock profitable?
Uniqure NV has a profit margin of -1236.0%. The company is currently unprofitable.
How often is the QURE DVR analysis updated?
Our AI-powered analysis of Uniqure NV is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 28, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for QURE (Uniqure NV) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.